KSI-301: Antibody Biopolymer Conjugate in Retinal Disorders

Overview

Journal Ther Adv Ophthalmol

Specialty Ophthalmology

Date 2021 Jul 22

PMID 34291186

Citations 20

Authors

Priya R Chandrasekaran

V G Madanagopalan

Affiliations

Soon will be listed here.

Abstract

KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials.

Citing Articles

Nanomedicine in Ophthalmology: From Bench to Bedside.

Mahaling B, Baruah N, Dinabandhu A J Clin Med. 2025; 13(24.

PMID: 39768574 PMC: 11678589. DOI: 10.3390/jcm13247651.

Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights.

Al Sakini A, Hamid A, Alkhuzaie Z, Al-Aish S, Al-Zubaidi S, Tayem A Int J Retina Vitreous. 2024; 10(1):83.

PMID: 39468614 PMC: 11514910. DOI: 10.1186/s40942-024-00603-y.

Comprehensive Pharmacokinetic Evaluation of High Melanin Binder Levofloxacin in Rabbits Shows Potential of Topical Eye Drops for Posterior Segment Treatment.

Bahrpeyma S, Jakubiak P, Alvarez-Sanchez R, Caruso A, Leuthardt M, Senn C Invest Ophthalmol Vis Sci. 2024; 65(12):14.

PMID: 39382881 PMC: 11469166. DOI: 10.1167/iovs.65.12.14.

Biopolymeric Innovations in Ophthalmic Surgery: Enhancing Devices and Drug Delivery Systems.

Wu K, Khan S, Liao Z, Marchand M, Tran S Polymers (Basel). 2024; 16(12).

PMID: 38932068 PMC: 11207407. DOI: 10.3390/polym16121717.

Understanding the Impact of Polyunsaturated Fatty Acids on Age-Related Macular Degeneration: A Review.

Brito M, Sorbier C, Mignet N, Boudy V, Borchard G, Vacher G Int J Mol Sci. 2024; 25(7).

PMID: 38612907 PMC: 11012607. DOI: 10.3390/ijms25074099.

References

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

Schmidt-Erfurth U, Kaiser P, Korobelnik J, Brown D, Chong V, Nguyen Q . Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2013; 121(1):193-201. DOI: 10.1016/j.ophtha.2013.08.011. View

Mesquida M, Drawnel F, Lait P, Copland D, Stimpson M, Llorenc V . Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro. Transl Vis Sci Technol. 2019; 8(5):32. PMC: 6819001. DOI: 10.1167/tvst.8.5.32. View

Gaudreault J, Fei D, Beyer J, Ryan A, Rangell L, Shiu V . Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007; 27(9):1260-6. DOI: 10.1097/IAE.0b013e318134eecd. View

Chalam K, Grover S, Sambhav K, Balaiya S, Murthy R . Aqueous interleukin-6 levels are superior to vascular endothelial growth factor in predicting therapeutic response to bevacizumab in age-related macular degeneration. J Ophthalmol. 2014; 2014:502174. PMC: 4121253. DOI: 10.1155/2014/502174. View

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

Korobelnik J, Holz F, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U . Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2013; 121(1):202-208. DOI: 10.1016/j.ophtha.2013.08.012. View

Brown D, Kaiser P, Michels M, Soubrane G, Heier J, Kim R . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-44. DOI: 10.1056/NEJMoa062655. View

Yancopoulos G, Davis S, Gale N, Rudge J, Wiegand S, Holash J . Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407(6801):242-8. DOI: 10.1038/35025215. View

10.

Wong W, Su X, Li X, Cheung C, Klein R, Cheng C . Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2):e106-16. DOI: 10.1016/S2214-109X(13)70145-1. View

11.

Samanta A, Aziz A, Jhingan M, Singh S, Khanani A, Chhablani J . Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). 2020; 9(3):250-259. PMC: 7299216. DOI: 10.1097/APO.0000000000000291. View

12.

Boyer D, Heier J, Brown D, Clark W, Vitti R, Berliner A . Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012; 119(5):1024-32. DOI: 10.1016/j.ophtha.2012.01.042. View

13.

Stewart M, Rosenfeld P . Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008; 92(5):667-8. DOI: 10.1136/bjo.2007.134874. View

14.

Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H . VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18(14):3964-72. PMC: 1171472. DOI: 10.1093/emboj/18.14.3964. View

15.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

16.

Schmid M, Bachmann L, Fas L, Kessels A, Job O, Thiel M . Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2014; 99(2):141-6. DOI: 10.1136/bjophthalmol-2014-305149. View

17.

Li J, Welchowski T, Schmid M, Mauschitz M, Holz F, Finger R . Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2019; 104(8):1077-1084. DOI: 10.1136/bjophthalmol-2019-314422. View

18.

Gadkari S, Maskati Q, Nayak B . Prevalence of diabetic retinopathy in India: The All India Ophthalmological Society Diabetic Retinopathy Eye Screening Study 2014. Indian J Ophthalmol. 2016; 64(1):38-44. PMC: 4821119. DOI: 10.4103/0301-4738.178144. View

19.

Whicher C, ONeill S, Holt R . Diabetes in the UK: 2019. Diabet Med. 2020; 37(2):242-247. DOI: 10.1111/dme.14225. View

20.

Al-Khersan H, Hussain R, Ciulla T, Dugel P . Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019; 20(15):1879-1891. DOI: 10.1080/14656566.2019.1636031. View